• Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kg
• Joenja is expected to become available to patients covered by the expanded indication in February 2027
• Marks another step in Pharming’s strategy to expand Joenja across age groups and international markets

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.